SecProbe.io

CORRESP
1
filename1.htm

              Harry
                S. Palmin

              hpalmin@novelos.com

              President
                and CEO

    VIA
      EDGAR

    Securities
      and Exchange Commission

    Division
      of Corporation Finance

    450
      Fifth
      Street, N.W.

    Washington,
      D.C. 20549

    June
      23,
      2008

            Re:

              Novelos
                Therapeutics, Inc.

    Registration
      Statement on Form S-1 (File No. 333-151396)

    Ladies
      and Gentlemen:

    Novelos
      Therapeutics, Inc., a Delaware corporation (the “Company”), has filed
      Registration Statement on Form S-1, File No. 333-151396 (the “Registration
      Statement”).

    Pursuant
      to Rule 461(a) under the Securities Act of 1933, as amended, the Company hereby
      requests that the effectiveness of the Registration Statement be accelerated
      so
      that the Registration Statement will become effective today, June 23, 2008,
      at
      4:30 p.m. EST, or as soon as practicable thereafter.

    The
      Company acknowledges that:

              ·

              should
                the Commission or the staff, acting pursuant to delegated authority,
                declare the filing effective, it does not foreclose the Commission
                from
                taking any action with respect to the
                filing;

              ·

              the
                action of the Commission or the staff, acting pursuant to delegated
                authority, in declaring the filing effective, does not relieve the
                Company
                from its full responsibility for the adequacy and accuracy of the
                disclosure in the filing; and

              ·

              the
                Company may not assert staff comments and the declaration of effectiveness
                as a defense in any proceeding initiated by the Commission or any
                person
                under the federal securities laws of the United
                States.

      Novelos
        Therapeutics, Inc.
        One
        Gateway Center, Suite 504 Newton, MA 02458 617.244.1616 Fax
        964.6331

    Please
      advise Paul Bork of Foley Hoag LLP at 617-832-1113 or, in his absence, Amanda
      Vendig at 617-832-3091, when the Registration Statement has been declared
      effective or if staff has any questions.

    Thank
      you
      for your cooperation.

              Very
                truly yours,

              Novelos
                Therapeutics, Inc.

              By:

              /s/
                Harry S. Palmin

              Harry
                S. Palmin, President and CEO

    cc: Paul
      Bork, Esq.

        -
          2 -